Dr Reddy's Laboratories Ltd (RDY) reports steady revenue growth driven by emerging markets and strategic collaborations, ...

Indian drugmaker Dr Reddy’s Laboratories Ltd. is planning to launch a generic version of Novo Nordisk A/S’s Ozempic in March ...

Welcome to the Dr Reddys Stock Liveblog, your ultimate source for real-time updates and analysis of one of the most prominent ...

Dr. Reddy’s Laboratories Limited (NYSE:RDY) Q3 2026 Earnings Call Transcript January 21, 2026 Dr. Reddy’s Laboratories ...

Dr. Reddy's Laboratories (NYSE:RDY) reported a “resilient performance” in its fiscal third quarter of FY26, with revenue growth and steady profitability despite what management described as ...

The total revenue of the Hyderabad based company grew 4.4% at ₹8,726 crore against ₹8,358 crore in the same period last year ...

Dr Reddy’s Laboratories reported Q3 net profit of ₹1,209 crore, beating estimates, while revenue and EBITDA also came in above expectations, though on a year-on-year basis, profit and EBITDA declined ...

Dr. Reddy's Laboratories Ltd. closed 10.01% short of its 52-week high of 1,377.95 rupees, which the company achieved on June 12th.

Welcome to the Dr Reddys Stock Liveblog, your go-to platform for real-time updates and analysis on a top-performing stock.

Consolidated revenue from operations rose by 4.4 per cent to Rs 8,726.8 crore in the third quarter, compared to Rs 8,358.6 ...

Dr. Reddy's Laboratories Ltd. closed 15.32% below its 52-week high of 1,377.95 rupees, which the company achieved on June ...

Dr Reddy's Laboratories share price jumps nearly 5% after Q3 results; revenue rises 4%, profit dips 14% YoY as brokerages stay mixed on outlook.